ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,473.23
0.77%
Dow Jones
38,778.10
0.49%
US Dollar vs MXN
18.4586
-0.42%
Brent Oil
83.48
-0.50%
Bitcoin
65,571.30
-1.38%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Arbutus Biopharma Corporation (ABUS)

  7. Arbutus Biopharma Corporation (ABUS) Noticias

ABUS

Arbutus Biopharma (ABUS)

Arbutus Biopharma Corporation
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ABUS
FechaHoraFuenteTítuloSímboloCompañía
06/06/202410:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
06/06/202410:15GlobeNewswire Inc.Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg LevelsNASDAQ:ABUSArbutus Biopharma Corporation
05/06/202401:30GlobeNewswire Inc.Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional CureNASDAQ:ABUSArbutus Biopharma Corporation
29/05/202406:30GlobeNewswire Inc.Arbutus to Participate in Jefferies Global Healthcare ConferenceNASDAQ:ABUSArbutus Biopharma Corporation
24/05/202415:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
22/05/202401:00GlobeNewswire Inc.Arbutus to Present Imdusiran Data at EASL Congress 2024NASDAQ:ABUSArbutus Biopharma Corporation
17/05/202408:03Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ABUSArbutus Biopharma Corporation
17/05/202408:00Business WireWhitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize ValueNASDAQ:ABUSArbutus Biopharma Corporation
09/05/202407:00Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:ABUSArbutus Biopharma Corporation
07/05/202406:30GlobeNewswire Inc.Arbutus to Participate in Two Upcoming Investor ConferencesNASDAQ:ABUSArbutus Biopharma Corporation
02/05/202406:30GlobeNewswire Inc.Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
02/05/202406:25GlobeNewswire Inc.Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024NASDAQ:ABUSArbutus Biopharma Corporation
18/04/202406:30GlobeNewswire Inc.Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
04/04/202407:30GlobeNewswire Inc.Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against ModernaNASDAQ:ABUSArbutus Biopharma Corporation
05/03/202415:48Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ABUSArbutus Biopharma Corporation
29/02/202406:30GlobeNewswire Inc.Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
15/02/202406:30GlobeNewswire Inc.Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
14/02/202415:38Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABUSArbutus Biopharma Corporation
08/01/202406:30GlobeNewswire Inc.Arbutus Announces 2024 Corporate Objectives and Provides Financial UpdateNASDAQ:ABUSArbutus Biopharma Corporation
21/11/202307:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ABUSArbutus Biopharma Corporation
08/11/202306:30GlobeNewswire Inc.Arbutus to Present at Jefferies London Healthcare ConferenceNASDAQ:ABUSArbutus Biopharma Corporation
07/11/202315:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABUSArbutus Biopharma Corporation
07/11/202306:30GlobeNewswire Inc.Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
07/11/202306:15GlobeNewswire Inc.Arbutus Announces CEO, William Collier, to Retire December 31, 2023NASDAQ:ABUSArbutus Biopharma Corporation
24/10/202306:30GlobeNewswire Inc.Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
18/10/202306:30GlobeNewswire Inc.Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual ConferenceNASDAQ:ABUSArbutus Biopharma Corporation
11/10/202307:05GlobeNewswire Inc.Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023NASDAQ:ABUSArbutus Biopharma Corporation
11/09/202315:15GlobeNewswire Inc.Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway ExtendedNASDAQ:ABUSArbutus Biopharma Corporation
03/08/202315:18Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ABUSArbutus Biopharma Corporation
03/08/202306:30GlobeNewswire Inc.Arbutus Reports Second Quarter 2023 Financial Results and Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
 Showing the most relevant articles for your search:NASDAQ:ABUS

Su Consulta Reciente

AMEX
SPY
SPDR S&P 500
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
JPM
JP Morgan Chase
NASDAQ
MSFT
Microsoft
USOTC
ADDYY
Adidas (QX)
SPI
SP500
S&P 500
FX
EURUSD
Euro vs US Dollar
NYSE
BAC
Bank of America
NYSE
VZ
Verizon Communications
NYSE
CVX
Chevron
CCOM
US500
US 500
NASDAQ
AAPL
Apple
NYSE
MRK
Merck
NASDAQ
GOOGL
Alphabet
COIN
ETHUSD
Ethereum
PM
XAUUSD
Gold vs US Dollar
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados